

Central Lancashire Online Knowledge (CLOK)

Title	Serotonin exerts a direct modulatory role on bladder afferent firing in mice
Type	Article
URL	https://clock.uclan.ac.uk/id/eprint/30681/
DOI	https://doi.org/10.1113/JP278751
Date	2019
Citation	Konthepakdee, N, Grundy, L, O'Donell, T, Garcia-Caraballo, S, Brierly, S, Grundy, D and Daly, Donna (2019) Serotonin exerts a direct modulatory role on bladder afferent firing in mice. The Journal of Physiology, 597 (21). pp. 5247-5264. ISSN 0022-3751
Creators	Konthepakdee, N, Grundy, L, O'Donell, T, Garcia-Caraballo, S, Brierly, S, Grundy, D and Daly, Donna

It is advisable to refer to the publisher's version if you intend to cite from the work.
<https://doi.org/10.1113/JP278751>

For information about Research at UCLan please go to <http://www.uclan.ac.uk/research/>

All outputs in CLOK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <http://clock.uclan.ac.uk/policies/>

Serotonin exerts a direct modulatory role on bladder afferent firing in mice

N Konthapakdee ¹, L Grundy ^{2,3,4}, T O'Donnell ^{2,3,4}, S Garcia-Caraballo ^{2,3,4}, S M. Brierley ^{2,3,4}, D Grundy ⁵ and D M Daly ⁶

Affiliations:

¹ Department of Physiology, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla 90112, Thailand.

² Visceral Pain Research Group, Centre for Neuroscience, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, 5042, Australia.

³ Hopwood Centre for Neurobiology, Lifelong Health Theme, South Australian Health and Medical Research Institute (SAHMRI), North Terrace, Adelaide, South Australia 5000, Australia.

⁴Centre for Nutrition and Gastrointestinal Diseases, Discipline of Medicine, University of Adelaide, North Terrace, Adelaide, South Australia 5000, Australia.

⁵ Department of Biomedical Science, University of Sheffield, Sheffield, England ⁶ University of Central Lancashire, Preston, England.

Running title: Effect of 5HT on afferent firing from the mouse bladder

Keywords: Afferent, bladder, serotonin, 5HT, visceral hypersensitivity

Co-corresponding authors

Professor David Grundy

Department of biomedical science

University Of Sheffield

Western bank

Sheffield

S10 2TN

d.grundy@sheffield.ac.uk.

Dr Donna Daly

School of Pharmacy and Biomedical Science

University of Central Lancashire

Fylde Road

Preston

PR1 2HE

Ddaly3@uclan.ac.uk

Key Points

- Functional disorders (i.e., interstitial cystitis/painful bladder syndrome and irritable bowel syndrome) are associated with hyperexcitability of afferent nerves innervating the urinary tract and the bowel respectively.
- Various non-5-HT₃ receptor mRNA transcripts are expressed in mouse urothelium and exert functional responses to 5-HT.
- Whilst 5-HT₃ receptors were not detected in mouse urothelium, 5-HT₃ receptors expressed on bladder sensory neurons plays a role in bladder afferent excitability under both normal conditions and in a mouse model of chronic visceral hypersensitivity (CVH).
- These data suggest that the role 5-HT₃ receptors play in bladder afferent signaling warrants further study as a potential therapeutic target for functional bladder disorders.

Abstract

Serotonin (5-HT) is an excitatory mediator, which in the gastrointestinal (GI) tract, plays a physiological role in gut-brain signaling and which is dysregulated in functional GI disorders such as irritable bowel syndrome (IBS). Patients suffering from IBS frequently suffer from urological symptoms characteristic of interstitial cystitis/painful bladder syndrome, which manifests due to cross-sensitization of shared innervation pathways between the bladder and colon. However, a direct modulatory role of 5-HT in bladder afferent signaling and its role in colon-bladder neuronal crosstalk remain elusive. The aim of this study was to investigate the action of 5-HT on bladder afferent signaling in normal mice and mice with chronic visceral hypersensitivity (CVH) following trinitrobenzenesulfonic acid (TNBS) induced colitis. Bladder afferent activity was recorded directly using *ex vivo* afferent nerve recordings. Expression of 14 5-HT receptor subtypes, the serotonin transporter (SERT) and 5-HT producing enzymes were determined in the urothelium using RT-PCR. Retrograde labelling of bladder projecting dorsal root ganglion (DRG) neurons was used to investigate expression of 5-HT₃ receptors using single cell RT-PCR, while sensory neuronal and urothelial responses to 5-HT were determined by live cell calcium imaging. 5-HT elicited bladder afferent firing predominantly via 5-HT₃ receptors expressed on afferent terminals. CVH animals showed a downregulation of SERT mRNA expression in urothelium, suggesting increased 5-HT bioavailability. Granisetron, a 5-HT₃ antagonist, reversed bladder afferent

hypersensitivity in CVH mice. These data suggest 5-HT exerts a direct effect on bladder afferents to enhance signaling. 5-HT₃ antagonists could therefore be a potential therapeutic target to treat functional bladder and bowel disorders.

Introduction

Information regarding the state of bladder distension is carried via sensory afferents that project via the pelvic and hypogastric nerves into the dorsal horn of the spinal cord, feeding into autonomic reflex and micturition centers within the brainstem to maintain continence (see Grundy *et al.* 2018a for review). Bladder afferents are found innervating both the detrusor smooth muscle and the urothelium (Spencer *et al.*, 2018), consisting of myelinated A δ fibres and unmyelinated C fibres that exhibit polymodal sensitivity to a host of mechanical and chemical stimuli (Su and Gebhart, 1998; Zagorodnyuk *et al.*, 2006; Zagorodnyuk *et al.*, 2007). Hypersensitivity of these bladder afferents to bladder distension may underlie the symptoms of urgency, frequency and nocturia in urological disorders such as overactive bladder syndrome (OAB) and interstitial cystitis/painful bladder syndrome (IC/PBS).

Serotonin (5-HT) is a key neuromodulator, regulating enteric and viscerosensory function as well as acting in the central nervous system (Berger *et al.*, 2009; Gershon and Tack, 2007; Grundy, 2008). Out of the seven members of the 5-HT receptor family (5-HT₁₋₇), six are G-protein coupled receptors (GPCRs) and one, the 5-HT₃ receptor is a ligand-gated ion channel (McCorvy and Roth, 2015). Within the bladder, activation of 5-HT_{1A}, 5-HT₂ and 5-HT₃, but not 5-HT₄ and 5-HT₇ can generate altered bladder contraction in rodent models (Chetty *et al.*, 2007; Kodama and Takimoto, 2000; Mittra *et al.*, 2007). 5-HT_{3A} and 5-HT_{3B} are expressed in the bladder urothelial layer and detrusor, where it is considered to play a role in neurogenic contraction (Chetty *et al.* 2007), whilst 5-HT receptor subtypes 5-HT_{1D}, 2A, 4 and 5-HT₆ are present in urothelial cells. 5-HT_{1A}, 1B, 1D, 2A, 2B, 2C, 3A, 4, and 5-HT₇ have also been reported in urothelium-denuded tissues (MatsumotoMiyai *et al.*, 2016). However, a modulatory role of 5-HT on bladder afferent excitability has yet to be explored.

Significant clinical comorbidity exists between a number of lower urinary tract and colonic disorders, such that the symptoms of bladder dysfunction, including urinary frequency, urgency, and pelvic pain are significantly more common amongst IBS patients than in

control groups (Daly and Chapple, 2013; Grundy and Brierley, 2018). Additionally, onethird of IC patients exhibit concurrent IBS symptoms including abdominal pain, discomfort, constipation and/or diarrhea (Aaron and Buchwald, 2001). The origin of these clinical co-morbidities is embedded within the physiological coordination of pelvic organs to provide efficient and synchronized defecation and micturition responses, and their shared innervation pathways within the DRG and spinal cord (Grundy et al., 2019). As such, sensitization of the afferents innervating one pelvic organ, has the potential to sensitize adjacent organs via cross-organ sensitization (Brumovsky and Gebhart, 2010; Christianson et al., 2007; Grundy et al., 2018b; Malykhina, 2007) .

2,4,6-trinitrobenzene sulfonic acid (TNBS) induced colitis is a commonly used animal model of IBS, triggering chronic visceral hypersensitivity (CVH) that persists after the initial inflammation has resolved (Castro et al., 2017; de Araujo et al., 2014; Hughes et al., 2009; Osteen et al., 2016). Furthermore, it has been shown that these CVH mice exhibit bladder afferent hypersensitivity and abnormal voiding patterns, characteristic of an 'overactive' phenotype (Grundy et al., 2018b). 5HT plays an essential role in health and the development of colonic afferent hypersensitivity associated with irritable bowel syndrome (IBS) in humans (Gershon and Tack, 2007; Grundy, 2008) and animal models (Keating et al., 2008; Linden et al., 2003; Linden et al., 2005). As such, this raises the possibility that bladder hypersensitivity associated with TNBS-induced colitis may involve a 5-HT₃ receptor dependent mechanism.

Therefore, we performed bladder afferent recordings to investigate the modulatory action of 5-HT on primary afferent signaling in mouse urinary bladder and in a TNBS-induced colitis model of colon-bladder neuronal 'cross talk'. We also used calcium imaging and single cell RT-PCR of retrogradely traced bladder-innervating afferent dorsal root ganglion (DRG) neurons to characterise the sensitivity of bladder neurons to 5-HT.

Methods

All experiments were conducted in Sheffield, UK except the induction of TNBS, the retrograde tracing studies and dorsal root ganglion (DRG) experiments (calcium imaging and single cell RT-PCR) which were performed in Adelaide, Australia.

Animals

All experiments performed in the UK used C57/BL6 adult male mice (12-16 weeks old, 25-30 g) from Charles River (Margate, UK). The animals were acclimatized for 7 days in the laboratory animal husbandry unit under 12-hr light/ 12-hr dark cycle and had free access to water and food. The animals were anaesthetized with isoflurane and humanely sacrificed by cervical dislocation according to UK home office legislation (Scientific procedure Act 1986) and in compliance with Journal of Physiology's ethical guidelines (Grundy, 2015).

Experiments performed in Australia were approved by and performed in accordance with the Animal Ethics Committees of the South Australian Health and Medical Research Institute (SAHMRI; Application # SAM190, SAM195, and SAM281). 12-16 week male and female mice were acquired from an in-house C57BL/6J breeding program (JAX strain #000664; originally purchased from The Jackson Laboratory; breeding barn MP14; Bar Harbor, ME) within SAHMRI's specific and opportunistic pathogen-free animal care facility. Mice were group housed (5 mice per cage) in specific housing rooms within a temperature-controlled environment of 22°C and a 12-hr light/ 12-hr dark cycle. Mice had free access to food and water.

2,4,6-trinitrobenzenesulfonic acid (TNBS) treatment

13-week old anesthetized male mice were intracolonicly administered with 2,4,6-trinitrobenzenesulfonic acid (TNBS) 0.01 mL (130 $\mu\text{g mL}^{-1}$ in 30% ethanol) via a polyethylene catheter to induce colonic inflammation. Histological examination of colon and bladder was performed to monitor mucosal architecture and signs of inflammation, i.e., cellular infiltration, crypt abscesses, and goblet cell depletion (data not shown). In this study we investigated the effect of TNBS colitis at 2 time points; acute TNBS (3 days post-treatment) when there is an active inflammatory state (termed acute visceral hyposensitivity, 'AVH') and 28 days post-treatment, when the inflammation has resolved but the bladder afferent hypersensitivity still persist (termed chronic visceral hypersensitivity, 'CVH'). For ex vivo experiments mice were humanely sacrificed by cervical dislocation.

Extracellular afferent nerve recordings

Bladder afferent nerve activity was determined using an *ex vivo* model previously described (Daly et al., 2007; Grundy et al., 2018a). The whole bladder and surrounding tissues (together with its emanating nerve fibers) was placed in a recording chamber (30 mL). The preparation was continuously perfused at a rate of 5 mL minute⁻¹ with oxygenated (95%O₂/5%CO₂) Krebs bicarbonate solution (composition, mM: NaCl 118.4, NaHCO₃ 24.9, CaCl₂ 1.9, MgSO₄ 1.2, KCl 4.7, KH₂PO₄ 1.2, glucose 11.7) at constant temperature of 35 °C. A polythene catheter (0.28 mm) was inserted into the urethra to perfuse the bladder with isotonic saline (0.9% NaCl) or pharmacological reagents using a perfusion pump (Genie, Kent, multi-phaser TM model NE-1000) with a rate 100 µL minute⁻¹. The bladder dome was punctured at the apex with a syringe needle (BD microlanceTM, 19G 2") and a dual- lumen catheter was inserted and secured with suture. One arm of the catheter was connected to a pressure transducer (DTXTM plus DT-XX, Becton Dickinson, Singapore) to monitor intravesical pressure and the other arm was connected to the 3 way tap to allow bladder filling (tap closed) or emptying (tap open). Multiunit pelvic and hypogastric nerves were dissected into a fine branches and placed into a suction electrode which was attached to a Neurolog headstage (NL 100, Digitimer, Ltd, UK), amplified with an AC amplifier (NL104) and filtered (NL125, band pass filter). The multi-unit afferent nerve discharge frequency (spikes/sec) was quantified using a spike processor (Digitimer D130). The signal was visualized on a computer running Spike 2 software (Version 7.1, Cambridge Electronic Design, UK).

Drug application

After a 30-minute stabilization period the bladder was distended by an intravesical infusion with saline at a rate of 100 µL minute⁻¹ to a maximal pressure 50 mmHg (control distensions). This was repeated at 10-minute intervals for 30-60 minutes to establish reproducible afferent responses before starting the protocol. After the control distensions, pharmacological agents were either perfused into the bladder lumen (intravesical application) or into the recording chamber (bath application). Following application of any compound a 'wash out' was conducted using either saline (intravesical) or Krebs (bath application) as appropriate for 30 minutes.

Isovolumetric protocol

In order to evaluate the effect of a pharmacological reagents on spontaneous afferent firing and bladder tone, isovolumetric experiments were conducted. After a 30-60 minute

stabilization period the bladder was filled to an intravesical pressure of 15 mmHg and left to stabilize for 30 minutes to allow the bladder to accommodate to the intravesical volume before bath application of agonists or antagonists. Nerve firing and bladder tone were continuously captured. Bladder contraction was determined as an increase in intravesical pressure.

Isolation of urothelial cells

Urothelial cells were isolated as previously described (Daly et al., 2014). The bladder was dissected longitudinally under a stereo microscope to expose the urothelium to the media (fresh Modified Eagle Media (MEM) (Gibco®) containing 0.7% HEPES and 1% antibiotic-antimycotic (PSF) solution (Gibco®) at 37°C and transferred to a Sylgard® (Dow Corning) coated dish. The tissue was stretched and pinned. The media was removed and replaced with 2.5 mg/mL dispase in MEM at 37°C. The bladder was incubated in dispase for 2 hours at room temperature. After the dispase had been aspirated, the urothelium was gently scraped with a scalpel under the stereo microscope and the cells were immediately placed in 0.5% trypsin-EDTA (Gibco®). The solution was incubated at 37 °C for 10 minutes, and gently triturated every a few minutes. The trypsinEDTA was deactivated by adding pre-warm MEM with 10 % Fetal Bovine Serum (FBS) (Gibco®). The cell suspension was centrifuged at 1500 rpm, 4 °C for 15 minutes. The solution was gently aspirated and the pellet was resuspended in pre-warmed Keratinocyte-serum free medium (K-SFM) and centrifuged at 1500 rpm, 4 °C for 15 minutes. For calcium imaging experiment, the cells were resuspended in K-SFM 200 µL and plated on collagen IV (Sigma Aldrich Poole, UK) coated coverslips in a 12 wells plate and incubated in 5% CO₂-95% O₂ at 37 °C overnight. For PCR experiments, the cell pellet was washed by adding PBS and centrifuged at 1000 rpm, 4 °C for 5 minutes and stored at -80 °C for RNA isolation process.

Reverse-transcription PCR (RT-PCR)

Urothelial cell pellets were used in this experiment. The total RNA was extracted using an RNeasy mini Kit (Qiagen, Valencia, CA, USA). RNA was transcribed to cDNA by High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Applied Biosystems, Carlsbad, CA, USA). PCR reactions were prepared using Gotaq® Green Master Mix (Promega M7121) according to manufacturer's instructions (Total volume 25 µL; Gotaq Gotaq® Green Master Mix 12.5 µL, forward and reward primers 2.5 µL, cDNA for 50 ng RNA, nuclease-free water was adjusted to volume 25 µL). The samples were run in

triplicate. The list of exon spanning primers used is summarised in Table 1. β -actin was used as a house keeping gene and either brain, DRG neurons, or duodenum was used as positive control. For negative control reactions, distilled water was used instead of cDNA samples. All the PCR products of detected 5-HT receptors were checked by DNA sequencing and all genes showed a high percentage matching (96-100%) to the original sequences, suggesting that the designed primers were efficient and the detected 5-HT receptor results were valid (data not shown).

Table 1 Summary of primer sequences used in RT-PCR

Receptor subtypes	Accession number	Primer sequences	Product size (bps)	Positive control
5-HT _{1A}	NM_008308	FW: 5' TAAGAACTTCCCGCTCCAGT 3' RW: 5' AGAAATGCAAGGGGATCTCC 3'	103	Brain
5-HT _{1B}	NM_010482	FW: 5' CCAACACACAATAAATGCTCCT3' RW: 5' CCAAGTCAAAGTGCGAGTCT 3'	135	DRG
5-HT _{1D}	NM_008309	FW: 5' TACAAACACCCCTACTAAACGC 3' RW: 5' ATGAGTGTTCAGCGTTGGTT 3'	310	DRG
5-HT _{1F}	NM_008310	FW: 5' GACCAGAGCCCCTTAGCTTC 3' RW: 5' TGCAGCTTCCGAGTCACAAT 3'	340	DRG
5-HT _{2A}	NM_172812	FW: 5' CATCTCCCTGGACCGCTAC 3' RW: 5' TCATCCTGTAGCCCGAAGAC 3'	150	DRG
5-HT _{2B}	XM_006529146	FW: 5' CCGATTGCCCTCTTGACAAT 3' RW: 5' GGCACAGAGATGCATGATGG 3'	120	DRG
5-HT _{2C}	NM_008312	FW: 5' TGAAACTGGTTGCTTAAACTGA 3' RW: 5' AGCTGCTACTGGACTTATGGA 3'	126	DRG
5-HT _{3A}	NM_013561	FW: 5' CCACCTTCCAAGCCAACAAG 3' RW: 5' CTCCCTTGGTGGTGGGAAGAG 3'	128	DRG
5-HT _{3B}	NM_020274	FW: 5' TGATTCTTCTGTGGTCCTGC 3'	154	DRG

		RW: 5' GCCTCAGCCCAGTTGTAAAC 3'		
5-HT ₄	NM_008313	FW: 5' ATGTTCTGCCTGGTCCGG 3'	162	DRG
		RW: 5' GCCTCCCAACATTAATGCGA 3'		
5-HT _{5A}	NM_008314	FW: 5' AAGACCAACAGCGTCTCCC 3'	124	Brain
		RW: 5' TCCACGTATCCCCTTCTGTC 3'		
5-HT _{5B}	NM_010483	FW: 5' TCTCCTTCGACGTGTTGTGC 3'	469	Brain
		RW: 5' GAGTCTCCGCTTGTCTGGAA 3'		
5-HT ₆	NM_021358	FW: 5' TGGGCAAAGCTCGAACATCT 3'	386	Brain
		RW: 5' GTCACATACGGCCTGAGCTAT 3'		
5-HT ₇	NM_008315	FW: 5' AAGTTCTCAGGCTTCCCACG 3'	485	DRG
		RW: 5' CAGTTTTGTAGCACAAACTCGCT 3'		
TPH1	NM_009414	FW: 5' CTAGGAGTTCATGGCAGGTG3'	83	Duodenum
		RW: 5' TTTCGAGTCTTTCAGTCACT 3'		
TPH2	NM_173391	FW: 5' TTCCCAGGGTCGAGTACACA 3'	216	Brain
		RW: 5' GTCTCTTGGGCTCAGGTAGC 3'		
SERT	NM_010484	FW: 5' CATAGCCAATGACAGACAG 3'	352	Duodenum
		RW: 5'CAAAACCAAGAACCAAGAC 3'		

256 Retrograde tracing of bladder innervating DRG neurons

257 A small aseptic abdominal incision was made in anesthetised (isoflurane 2-4 % in
258 oxygen) mice. Cholera toxin subunit B conjugated to AlexaFluor® 488 (CTB-488; 0.5 %
259 diluted in 0.1 M phosphate buffered saline (PBS); ThermoFisher Scientific) was injected
260 at four sites into the bladder wall (2µL / injection) using a 5 µl Hamilton syringe attached
261 to a 23-gauge needle. The abdominal incision was sutured closed and analgesic
262 (Buprenorphine; 2.7µg / 30g) and antibiotic (Ampicillin; 50 mg/kg) given subcutaneously
263 as mice regained consciousness. Mice were allowed to recover, housed individually and
264 monitored for four days, in order to visualize CTB-labelled afferent neurons in the DRG.

Isolation of DRG neurons

DRGs from lumbosacral (L5-S1) spinal levels of the mouse spinal cord, which correspond to the pelvic innervation of the bladder, were isolated and incubated in Hanks balanced salt solution (HBSS) (pH 7.4) containing collagenase (4mg/mL), and dispase (4.5mg/mL), at 37°C for 30 minutes. The collagenase/dispase solution was aspirated and replaced with HBSS containing collagenase (4mg/mL) for 10 minutes at 37°C. The collagenase solution was aspirated and replaced with 600µl DMEM (GIBCO) containing 10% FCS (Invitrogen), 2 mM L-glutamine (GIBCO), 100 µM MEM non-essential amino acids (GIBCO) and 100 mg/ml penicillin/streptomycin (Invitrogen). Neurons were dissociated via trituration with a Pasteur pipette and spot plated onto 15 mm coverslips coated with laminin (20 µg/mL) and poly-D-lysine (800 µg/mL) and maintained in an incubator at 37 °C in 5% CO₂. Calcium imaging recordings were performed on DRG neurons 18-30hrs post isolation.

Single cell RT-PCR

Cells were used 3-8 hrs after plating a cover slips. Under continuous perfusion of sterile and RNA-/DNase-free PBS, retrogradely traced single DRG neurons (N=3/group; HC: total 77 cells, CVH: total 74 cells; 23-27 cells per mouse) were identified using a fluorescent microscope and picked using a micromanipulator into the end of a fine glass capillary. The glass capillary containing the cell was then broken into a sterile Eppendorf tube containing 10 µL of lysis buffer with 1µl DNase (TaqMan Gene Expression Cell-to-CT Kit; Life Technologies). Samples were treated according to manufacturer's instructions for cDNA synthesis using SuperScript™ VILO™ cDNA Synthesis Kit (ThermoFisher Scientific) and RT-PCR using TaqMan™ Universal Master Mix (ThermoFisher Scientific). Ready-made TaqMan probes were purchased from LifeTechnologies (Htr3a: Mm00442874_m1). For each coverslip of cells, a bath control was also taken and analysed together with cells. A total of 45 cycles was run and only samples with a complete amplification curve were considered as positive. After lysis and termination of DNase treatment, samples were immediately frozen on dry ice and stored at -80°C until cDNA synthesis was performed. Tubulin-3 expression (Mm00727586_m1) served as a neuronal marker and positive control and for every coverslip a bath control was taken and analysed together with other samples. GFAP expression (Mm01253033_m1) was measured to exclude contamination with glial cells. PCR products were stored at -20C and resolved on a 3-4% TBE agarose gel (UltraPure

Agarose 1000, cat#16550-100, Invitrogen). All samples were visualized by adding 1µl of Midori Green Direct (NIPPON Genetics) to 20µl of sample and 5µl of samples was loaded onto wells. A 20bp marker (BioRad) was used to check for correct size.

Quantitative real-time RT-PCR

To determine the quantitative expression of TPH1 2 and SERT in urothelial cell samples from sham and TNBS treated animals, quantitative RT-PCR was used. The quantification of mRNA expression determined using TaqMan Gene Expression Master Mix (Applied Biosystems 4374657). The reaction was prepared on ice and mixed in Hard-Shell® ThinWall 96-Well Skirted PCR Plates (BIO-RAD, HSP-9665). Prior to running the reactions, the plates were covered with MicroAmp™ Optical Adhesive Film for 96-Well Plates (Applied Biosystems, 43111971) and centrifuged briefly to spin down the contents and eliminate any air bubbles from the solutions. The reaction for each sample and gene was run in duplicate. DNase free water was used to replace cDNA as a negative control for each gene and plate. PCR reactions were performed in a BIO-RAD CFX96 Touch™ Real-time thermocycler (C1000 Touch™ Thermal Cycler, Bio-Rad Laboratories Ltd. Hercules, USA). Results were expressed as relative expression to the housekeeping gene GAPDH ($1/\Delta Ct$), and fold change was calculated using the equation $2^{-\Delta(\Delta Ct)}$.

Calcium imaging

Cultured DRG neurons (18-30 hours) or isolated urothelial cells were loaded with 2 µM fura-2-acetoxymethyl ester (Fura-2) for 15 minutes at 37°C and washed with HEPES buffer (10mM, NaCl 142mM, KCl 2mM, glucose 10mM, CaCl₂ 2mM, MgCl₂ 1mM, HEPES 10mM; pH 7.4) for 30 minutes prior to imaging at room temperature (23°C). Fura-2 was excited at 340 and 380 nm. Fluorescence images were obtained every 5s using a 20x objective. Retrogradely traced bladder-innervating DRG neurons were identified by the presence of the CTB-488 tracer. Data were recorded and analysed using MetaFluor software. After an initial baseline reading to ensure cell fluorescence was stable (an indication of healthy cells), DRGs and/or urothelial cells were stimulated with either 5-HT (100 µM), 2-Me-5HT (100 µM) in the absence or presence of granisetron (1 µM), and changes in intracellular calcium [Ca^{2+}]_i were monitored in real-time. Ionomycin or KCl (40 mM) was applied as a positive control for cell viability.

Drugs and solutions

5-hydroxytryptamine (5-HT) and 5-methoxytryptamine (5-MT) were obtained from Sigma Aldrich, UK. 2-Methoxy-5-hydroxytryptamine (2-Me-5-HT) was obtained from Tocris/Bioscience, UK. Granisetron hydrochloride was obtained from LKT Laboratories, USA. ML-9 was obtained from Cayman Chemical. Y-27632 was obtained from Chemdea, USA.

Data analysis

Spontaneous afferent firing (also referred to as baseline) was determined by measuring mean action potential firing rate over 10 seconds either at rest (before a drug application or before a distension). This is defined as the afferent activity arising from the bladder in the absence of a stimuli (mechanical or chemical). Mechanosensitive afferent firing was determined by performing ramp distension of the bladder (as described above) and measuring the afferent discharge at various intravesical pressure points using a custombuilt script from SPIKE 2 version 7 (CED, UK). Data are expressed as means $\pm$ SEM. Statistical analysis was analyzed using one- or two-way analysis of variance (ANOVA) with Dunnett's or Tukey multiple comparison or Student's *t* test, where appropriate. The statistical analysis were considered significant at * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.

Results

Intravesical administration of 5-HT agonists excites bladder afferent nerves In order to determine if bladder afferents functionally express 5-HT receptors, we investigated the effects of various 5-HT receptor agonists on *ex-vivo* bladder afferent nerve activity. We found that intravesical infusion of 5-HT (100 μ M), evoked a dramatic and sustained increase in baseline afferent nerve firing compared to intravesical saline (Fig. 1A, 1B). The receptor mechanisms underlying this effect were determined by comparing the responses to 2-Me-5-HT, a selective 5-HT₃ agonist (100 μ M), with 5-MT (100 μ M) a compound which exhibits selectivity for the GPCR family of 5-HT receptors including 5-HT₁, 5-HT₂ and 5-HT₄₋₇. The responses to application of 5-HT and 2-Me-5HT were comparable. However while the response to 5-MT, was significantly increased relative to baseline, the magnitude of the firing was reduced compared to that of 5-HT and 2-Me-5-HT (Fig. 1C, 1D). These data suggest that multiple 5-HT receptors may influence bladder afferent firing, and that this may occur via both direct and indirect mechanisms.

5-HT receptors are expressed on bladder urothelium

Given the established role of the urothelium as a sensory structure, we wanted to determine if the effects of intravesical 5-HT on bladder afferent firing were secondary to activation of urothelial cells or a consequence of direct activation of primary afferent endings innervating the bladder. To this end we investigated serotonergic receptor expression in the bladder urothelial layer using RT-PCR. The expression profile for the various 5-HT receptors in the urothelium is shown in Figure 2. Overall, 5-HT_{1A}, 5-HT_{1B}, 5-HT_{1D}, 5-HT_{2A}, 5-HT_{2B}, 5-HT₄, 5-HT₆, and 5-HT₇ receptors were all detected. In contrast, 5-HT_{1F}, 5-HT_{2C}, 5-HT_{3A}, 5-HT_{3B} or the 5-HT_{5A}, 5-HT_{5B} receptors were not detected in the bladder urothelium. Moreover, expression of the 5-HT producing enzymes, tryptophan hydroxylase-1, and 2 (TPH-1 and TPH-2), and the sodium-dependent serotonin transporter (SERT) transcripts were also examined using PCR and all three were shown to be expressed in the urothelium (Fig. 2). This finding raises the possibility of an endogenous source of 5-HT in the bladder wall.

Stimulation of non-5HT₃ receptors on the urothelium can evoke urothelial cell activation

Calcium imaging of isolated primary mouse urothelial cells (PMUCs) was conducted to investigate the functionality of 5-HT receptors in the urothelium. Incubation of PMUCs

with 5-HT triggered an increase in intracellular Ca^{2+} indicative of cellular activation. Consistent with our RT-PCR data identifying an absence of 5-HT₃ receptor expression in the urothelium, both the magnitude of the response to 5-HT and the number of responding cells was unchanged following incubation with the 5-HT₃ selective antagonist granisetron (Fig. 3B, 3C).

Activation of 5-HT receptors by bath application of agonist alters afferent nerve firing from the bladder and induces contraction of the detrusor

To elucidate if the 5-HT effects on bladder afferent activity are secondary to induced detrusor contraction, we applied agonists, antagonist and muscle contraction inhibitors under isovolumetric bladder conditions to determine their effect on spontaneous afferent firing and associated intravesical pressure changes. A representative trace of extraluminal 5-HT application on bladder afferent firing and intravesical pressure is illustrated in Fig. 4A. We found that 5-HT (100 μM), 2-Me-5-HT (100 μM) or 5-MT (100 μM) all evoked a marked increase in bladder afferent nerve firing, and a small but robust increase in intravesical pressure indicating detrusor contraction (Fig. 4B, 4C).

The peak afferent response to bath application of 5-HT and 2-Me-5-HT was similar. Moreover, application of the selective 5-HT₃ receptor antagonist, granisetron (1 μM), significantly attenuated afferent responses to 5-HT. To uncouple the direct effect of 5HT on the afferent nerves from any indirect nerve response produced by bladder contraction we used a myosin light chain kinase inhibitor (ML-9, 10 μM) and/or the rhoassociated kinase inhibitor (Y-27632, 10 μM) to prevent contraction. Under such conditions the afferent response to 5-MT was abolished in the absence of contraction, suggesting that the response to 5-MT was secondary to changes in muscle tone. Conversely, the afferent response to 2-Me-5-HT persisted despite the absence of contraction, suggesting that the contractile and nerve responses to 5-HT₃ receptor stimulation were independent (Fig. 4B and 4C).

Chronic visceral hypersensitivity evoked with intra-colonic TNBS caused altered mechanosensitivity and increased spontaneous afferent firing from the bladder, an effect that was reversed by blocking the 5-HT₃ receptor.

Bladder hypersensitivity has been described in response to colonic inflammation, a phenomenon referred to as cross-organ sensitization. Since 5-HT is implicated in colonic hypersensitivity we investigated the extent to which it may contribute to altered bladder

afferent signalling in a mouse model of TNBS-induced colonic inflammation. We examined 2 time points representing acute inflammation (3 days post-treatment) and a chronic state in which inflammation had resolved (28 days post-treatment). Acute TNBS treatment had no significant effect on spontaneous nerve firing from the bladder and caused a moderate (~25% from sham control) decrease of mechanosensitive afferent firing at 50 mmHg (Fig. 5A). Conversely, in the post-inflammatory CVH state there was a significant increase in spontaneous bladder afferent firing (~160%) and in the afferent response to bladder distension (~27%) when compared to sham controls (*P<0.05, Fig 5). Treatment with granisetron (1 µM) prior to 5-HT application normalized both the spontaneous bladder discharge and the mechanosensitivity observed in the CVH model (Fig. 5A, 5B).

SERT mRNA expression was downregulated in urothelial cells of CVH mice.

The attenuated responses in the presence of granisetron implies a role for endogenous 5-HT in bladder hypersensitivity. We hypothesized that there might be a change in 5-HT bioavailability in the urothelium following chronic visceral hypersensitivity (CVH) induced by intra-colonic TNBS. Quantitative RT-PCR showed that the level of SERT mRNA expression was significantly lower in urothelial cells from bladders in TNBS treated mice compared to sham operated controls (*P<0.05, Fig. 6A). TPH1 and TPH2 mRNA expression was also reduced, but because of the large variability, especially in TPH1 levels, this did not reach significance (Fig. 6B, 6C). Nevertheless, these data are consistent with a role for urothelial 5-HT in bladder hypersensitivity.

Bladder projecting DRG neurons express 5-HT₃ receptors in both control and CVH mice and display functional response to 5-HT and 2-Me-5-HT activation.

To examine if 5-HT₃ receptors in the afferent terminals play a role in 5-HT-sensitized bladder afferent firing, we performed retrograde labelling and single cell RT-PCR to examine 5-HT₃ receptor gene expression in bladder-projecting DRG neurons. The vast majority of these neurons (91%, 70/77 neurons) expressed 5-HT₃ receptors even in control animals, which is striking given the absence of any previously documented endogenous source of 5-HT. Moreover, 95% of bladder-innervating DRG isolated from mice with CVH expressed 5-HT₃ (70/74 neurons), showing a small increase in the number of neurons expressing 5-HT₃ occurs during cross-organ sensitization. (Fig. 7A).

In addition, we performed calcium imaging on bladder innervating (traced) and nontraced lumbosacral DRG neurons. A representative trace of calcium imaging of lumbosacral DRG neurons in response to 5-HT (100 μ M) and 2-Me-5-HT (100 μ M) is shown in Figure 7B. 60 out of a total of 69 (87%) bladder projecting DRG neurons (traced neurons) elicited a calcium signal in response to application of 5-HT, moreover a significantly greater proportion of the traced DRGs responded to 5HT than the non-traced DRG neurons. This indicates that expression of 5-HT receptors maybe enriched in bladder neurons compared to the generalized neuronal population. In addition, a similar proportion of traced neurons (70%, 36/51) showed an increase in Ca^{2+} influx after the application of 2-Me-5-HT (Fig. 7C). The magnitude of the Ca^{2+} response to 5-HT and 2Me-5-HT was similar in traced and non-traced DRG neurons (Fig. 7D). These data are consistent with a major contribution of 5-HT₃ receptors to 5-HT's ability to sensitize bladder afferents and enhance firing.

Discussion

Over the past decade, a number of studies, including our own, have investigated the chemical and mechanical stimuli that drive afferent transmission from the bladder. Despite this, the mechanisms involved in generating bladder hypersensitivity still remain elusive. There is significant clinical comorbidity between hypersensitivity disorders of the bladder and hypersensitivity disorders of the colon (such as IBS), pointing to a common underlying etiology involving dichotomizing afferent fibres between the bladder and bowel (Grundy and Brierley, 2018; Malykhina, 2007). Serotonin (5-HT) plays integral roles in secretion, motility and visceral sensitivity of the GI tract (Grundy, 2008). However, relatively little is known about how 5HT affects afferent signaling from the bladder in healthy or hypersensitivity states. In this study we investigated the modulatory action of 5-HT on primary afferent signaling in the mouse urinary bladder and in a TNBSinduced model of colitis which induces colon-bladder cross-organ sensitization (Grundy et al., 2018b).

5-HT increases bladder afferent firing and induces contraction of the detrusor

Stimulation of 5-HT receptors with serotonin caused a large increase in bladder afferent nerve firing, which was concomitant with a small but significant contraction of the bladder. When the contraction was blocked using a combination of muscle blockers the sensory response was significantly attenuated. This suggests that a proportion of the afferent response to 5-HT occurred via the activation of mechanosensory afferent nerves which

were activated in response to bladder contraction. However, since the afferent response to 5-HT was only partially reduced, it is also likely that there was also an additional direct mechanism by which 5-HT stimulated a receptor(s) on the nerve terminal, inducing nerve firing in a mechanism that was independent from changes in the muscle tone.

Similar to 5-HT, bath application of the selective 5-HT₁, 5-HT₂, 5-HT₄, 5-HT₆, and 5-HT₇ agonist, 5 methoxy tryptamine (5-MT) also caused an increase in afferent nerve firing and evoked a small contraction of the bladder. However, when the contraction was blocked by preincubation with the muscle blockers (Y-27632 and ML-9), the contraction was lost and the afferent response to 5MT was abolished suggesting that the afferent response to stimulation of the non-5HT₃ receptor populations was secondary to changes in bladder contraction rather than via a direct action at the afferent terminal. A number of previous studies have demonstrated that 5-HT can induce contraction of bladder muscle strips *in vitro*, however the receptor that mediates the contraction remains controversial. Hattori *et al.*, (2017) show that both 5-HT and a selective 5-HT₂ receptor agonist cause contraction of the bladder, but a lack of efficacy following pre-incubation of selective 5HT₂ receptor antagonists suggested that the effect was not mediated by the 5-HT₂ receptor (Hattori et al., 2017). In another study it was shown that 5-HT potentiates neurogenic contractions of rat isolated detrusor muscle through both 5-HT₇ and 5-HT_{2c} receptors (Rekik et al., 2011). Moreover, in the guinea pig the contractile response to 5HT was suggested to be via the 5-HT₂, 5-HT₃ and 5-HT₄ receptors (Yoshida et al., 2002).

5-HT has a direct effect on afferent firing via the 5-HT₃ receptor

Bath application of 2-Me-5-HT caused a robust increase in nerve firing that was not affected by blocking contractility. 2-Me-5-HT is a potent agonist of both the 5-HT₃ and the 5-HT₆ receptor (Glennon et al., 2000) suggesting that activation of either 5-HT₃ or 5HT₆ located on the urothelium (in the case of 5HT₆) or at the nerve terminal results in afferent nerve firing from the bladder. Since we did not use a selective 5HT₆ receptor antagonist we cannot determine from these data what contribution 5HT₆ made to the 2Me-5-HT response. Since the role of 5HT₆ in the lower urinary tract is relatively understudied this would warrant further investigation. However in this study we focused on the 5-HT₃ receptor since pre-incubation of the 5-HT₃ selective antagonist granisteron inhibited the 5-HT-mediated increase in bladder afferent nerve firing by ~65%. Since 5HT₃ receptors were not identified in the urothelium via RT-PCR, this suggests that stimulation of 5-HT₃ receptors can elicit a direct increase in afferent nerve firing by stimulating receptors on

the nerve terminal rather than via an indirect mechanism as a result of muscle contraction or urothelial signaling. Our retrograde tracing studies revealed that the majority of lumbosacral DRG neurons innervating the mouse urinary bladder (90%) express the 5-HT₃ receptor. Furthermore, our functional calcium imaging showed that the majority of these DRGs exhibit functional responses to 5-HT (87%) and the 5-HT₃ selective agonist, 2-Me-5-HT (70%). In this study we did not stain the afferent terminals and show expression of 5HT₃ in bladder afferent endings, although it is well established that expression in the cell body where the receptor is synthesized is likely to be indicative of expression at the afferent terminal. Therefore these data suggest that 5HT exerts a direct action on 5-HT₃ receptor at the terminal endings of the primary afferents innervating the bladder. This idea is supported by previous studies which show that 5-HT₃ receptors are also located in rat DRG neurons (Nicholson et al., 2003) and that systemic injection of a 5-HT precursor (5-hydroxytryptophan, 5-HTP), triggers bladder hyper-excitability in a mechanism mediated by spinal 5-HT₃ receptors (Hall et al., 2015).

A recent study has also shown that bladder-projecting neurons in the caudal raphe nucleus, the area of the brainstem which exhibits supraspinal control of the bladder, also express serotonin (Ahn et al., 2018), suggesting that serotonergic control of the bladder could have both peripheral and central components which involve the 5-HT₃ receptor.

5-HT can alter signaling in the urothelium in a mechanism that is independent of the 5-HT₃ receptor

Over the past decade it has become increasingly clear that the urothelium of the bladder plays an active role in sensation. It is responsive to bladder filling and releases an array of mediators and neurotransmitters which target underlying afferent nerves to modulate firing (urothelial- afferent signaling). Since 5-HT receptor agonists altered sensory signaling from the bladder we wanted to determine what role the urothelium played in the afferent response. mRNA for 5-HT_{1A}, 5-HT_{1B}, 5-HT_{1D}, 5-HT_{2A}, 5-HT_{2B}, 5-HT₄, 5-HT₆, and 5-HT₇ receptors were identified in the urothelium and our functional calcium imaging experiments demonstrated that ~60% of isolated primary urothelial cells were activated by stimulation with 5-HT. This indicates that there may be functional 5-HT receptors in the urothelium that could play a role in both autocrine urothelial mechanisms and paracrine sensory mechanisms. It is important to note that we did not conduct any western blot analysis or immunocytochemistry to confirm the protein expression of these receptors in the urothelium, nor did we use an array of selective agonist and antagonists

in the calcium imaging experiments, this makes it difficult for us to identify which receptor(s) mediate the calcium responses. However, pretreatment with the 5-HT₃ selective antagonist, granisetron had no effect on the magnitude of the calcium signals or on the numbers of responsive cells. This taken together with the fact that mRNA for the 5-HT₃ receptor was not identified in the urothelium suggests that while the 5-HT₃ receptor may be involved in the direct afferent response to 5HT (i.e. at the 5-HT₃ receptor on the primary afferent terminal) it is not involved in urothelial signaling. Further studies are required to delineate the differential role that non-5HT₃ receptors play in mediating contractility and urothelial signaling in the bladder.

5-HT₃ receptor mechanisms contribute to bladder hypersensitivity in CVH.

Christianson *et al.*, (2007) demonstrated that 21% of all retrograde traced mouse DRGs from the colon also innervated the bladder (dichotomizing neurons) (Christianson *et al.*, 2007). Since co-morbidities between the bladder and bowel are common, the hypothesis of 'cross-organ sensitization' has emerged. Evidence for this phenomenon has come from pre-clinical studies identifying that inflammation or injury to one organ, such as the bowel, can lead to changes in the sensitivity of another closely located organ, such as the bladder, via these convergent neural pathways. A number of models of colon-bladder cross organ sensitization have been developed to study this phenomenon, one such model is the well-established TNBS model of colitis (Antonίου *et al.*, 2016; Grundy *et al.*, 2018b; Malykhina *et al.*, 2006; Qin *et al.*, 2005). Previous studies using the TNBS induced colitis model suggest that inflammation of the bowel induces hypersensitivity of colonic afferents and changes in spinal neural circuitry that persists after the inflammation as resolved (Brierley and Linden, 2014). This effect is concomitant with hypersensitivity of the bladder and bladder voiding dysfunction indicative of overactive bladder syndrome or painful bladder syndrome, without any obvious morphological changes in bladder structure. Two phases of response have been identified; an acute phase of visceral hyposensitivity (AVH, <15 days post treatment) and a chronic phase of visceral hypersensitivity (CVH, >28 days post treatment) (Grundy *et al.*, 2018b).

The 5HT₃ receptor has been linked to intestinal dysfunction in a number of studies. For example, the selective 5-HT₃ antagonists tropisetron and ondansetron significantly reduce signs of inflammatory damage in the bowel in a TNBS-induced colitis model in the rat (Motavallian-Naeini *et al.*, 2012; Motavallian *et al.*, 2013). Bioavailability of 5-HT in the bowel, as measured by expression of the serotonin reuptake transporter (SERT),

is reduced in mice (Linden et al., 2005), guinea pigs (Linden et al., 2003) and humans with either inflammatory conditions of the bowel or irritable bowel syndrome (Coates et al., 2004). In addition, in a *Trichinella spiralis* induced model of post-infectious IBS, longterm hypersensitivity of the small intestine was shown to be mediated by changes in 5HT₃ receptor expression (Keating et al., 2008).

In the present study, after the induction of colitis with TNBS, the afferent response to bladder distension was actually inhibited by ~20%, suggesting hyposensitivity of the bladder afferent nerves in the acute phase colitis. However, in the post-inflammatory pahse of CVH, the afferent response to bladder distension was significantly increased. This is consistent with previous data (Grundy et al., 2018b), and suggests that there was long-term hypersensitivity of bladder afferents following inflammation of the bowel. Interestingly, the distension-induced hypersensitivity was attenuated via pretreatment with the 5-HT₃ selective antagonist granisetron, implicating the 5-HT₃ receptor in the response. The numbers of bladder-projecting DRG neurons expressing 5-HT₃ was also slightly elevated in the CVH phase.

Interestingly, mRNA for the 5-HT producing enzymes, TPH1 and TPH2, and the serotonin transporter, SERT was detected in the normal urothelium and in the urothelium of mice following TNBS. However, in the urothelium of CVH mice we observed a significant decrease in SERT expression, which may suggest that following colonic inflammation there were alterations in the bioavailability of 5-HT. This could potentially lead to reciprocal changes in 5-HT₃ receptor sensitivity and bladder afferent hypersensitivity.

What is the endogenous source of 5-HT in the bladder?

The majority of 5-HT in the body is produced by enterochromaffin cells in the GI tract (Gershon and Tack, 2007) and in the CNS. Activation of enterochromaffin cells can lead to the release of 5-HT and activation of 5-HT₃ receptors on colonic afferents innervating the colonic mucosa (Bellono et al., 2017). In addition, mast cells also synthesize 5-HT from 5-hydroxytryptophan and express TPH1 in the rat and human gastrointestinal tracts (Dwyer et al., 2016; Weitzman et al., 1985). However, the endogenous source of 5-HT in the bladder has yet to be identified. Since the components needed to produce 5-HT are present in the urothelium (ie TPH1 and TPH2 mRNA), it is possible that urothelial cells produce and release 5-HT which can then exert actions on afferent nerve fibers located in close proximity, or the underlying smooth muscle. Despite the presence of the

molecular architecture responsible for 5-HT synthesis we identified within the urothelium, there have been no previous reports of 5HT release from the bladder in the literature to support this idea. (Fitzgerald *et al.* (2013) showed that there was a significant increase in the number of mast cells in the bladder at 12 days after colonic TNBS administration in rats, raising the possibility that in the post-inflammatory state, 5-HT levels in the bladder rise due to infiltration of circulating mast cells (Fitzgerald *et al.*, 2013). This mechanism could drive altered sensory activity via an interaction with the 5-HT₃ receptor on the primary afferents. Unfortunately, since we did not measure 5-HT levels or mast cell numbers in the bladders from our CVH mice this remains speculative.

Recent studies have demonstrated the presence of 5-HT positive paraneurons in the mouse urethra which have a close association with urethral afferent nerves (Kullmann *et al.*, 2018). In our extracellular recordings the primary afferents we recorded from lie in close proximity to the bladder neck. Early work by Gabella and Davis demonstrated that the majority of afferent innervation to the bladder lies in the lower 1/3 of the bladder body (Gabella and Davis, 1998). Since our electrophysiological recordings consist of multi-unit nerve bundles it is possible that some of the afferents that we recorded from emanated from the bladder neck and urethra. Moreover, it is also possible that the urethral paraneurons could provide an endogenous source of 5-HT, which when released in the urethra either 'diffuses' to reach some of the bladder projecting afferents or via the urethral urothelium alters urothelial- afferent signaling in the bladder body. A recent *in vivo* study lends support to this idea showing that 5-HT released by the urothelial cells located in the urethra can actually activate a urethra-vesical pathway to enhance contraction of the bladder (Coelho *et al.*, 2018). This is a fascinating area for further research and further highlights the complexity of signaling in the lower urinary tract.

Translational Perspectives

These data suggest that 5-HT plays a key role in the modulation of bladder sensory firing and the generation of visceral hypersensitivity. This may have important implications for understanding normal function of the bladder and the changes in bladder function that arise when serotonergic signaling is disrupted, such that occurs in IBS or with depression and anxiety.

669

670

671

672

673

674

675

Figures and legends







Figure 1 Intravesically applied 5-HT, 2-Me-5HT and 5-MT stimulated bladder afferent firing. (A) Representative trace to illustrate the afferent response to intravesical application of 5-HT (100 μ M). (B-D) The peak afferent response to intravesical application of (B) 5-HT (100 μ M), (C) 2-Me-5HT (100 μ M) and (D) 5-MT (100 μ M). Overall, 5-HT, 2-Me-5-HT and 5-MT all evoked increased in afferent firing above baseline (* $P < 0.05$), paired Student's t-test. Each dot represents data from a single preparation (N).






Figure 2 mRNA expression of 5-HT receptors, TPH1, TPH2, and SERT on the mouse urothelium. An array of 5-HT receptor transcripts were detected in mouse urothelial cell lysates (5-HT_{1A}, 1B, 1D, 2A, 2B, 4, 6, 7). 5-HT_{1F}, 2C, 3A, 3B, 5A, and 5B receptors were not detectable. mRNA expression of TPH1, TPH2, and SERT were detected in mouse urothelial cells. β -actin was used as a house keeping gene. Duodenum was used as a positive control of TPH1 and SERT. Brain was used as a positive control for TPH2 (N=3 mice per tissue).

A



B



C






Figure 3 5- HT stimulated mouse urothelial cells through a non- 5- HT3 receptor mechanism. (A) A sample trace showing the calcium response of isolated primary mouse urothelial cells to 5-HT (100 μ M) and ionomycin (5 μ M) . Each line represents a single urothelial cell. **B)** The relative increase of intracellular Ca^{2+} (Ratio 340/ 380) in response to 5- HT with and without preincubation with granisetron (1 μ M), showing that granisetron did not affect 5HT responses. (**C)** The percentage of cells responding to 5- HT after preincubation of granisetron, paired Student's t-test, (5-HT, N=6 mice, n=137 cells vs. Granisetron with 5-HT, N=5 mice, n=115 cells), unpaired Student's t-test. N refers to number of animals and n indicates number of cells.

A



B



C






Figure 4 5-HT₃ receptors play a role in mediating the action of 5-HT on bladder afferent firing and this effect is independent of detrusor contraction. (A) A representative trace showing the effect of bath applied 5-HT on afferent nerve firing and detrusor tone. 5HT, 2-Me-5-HT and 5-MT all evoked an increase in nerve firing which was concomitant with a small but significant bladder contraction. (B) The afferent response to bath application of 5-HT, 2-Me5-HT, 5-MT with and without pre-incubation of the 5-HT₃ receptor antagonist granisetron and/or smooth muscle blockers (Y-27632 and ML-9) (C) The effect of the same pharmacological agents on detrusor contractility. Data are represented as mean $\pm$ SEM, each symbol represents a single N number, *P<0.05, **P<0.01, ***P<0.001, One-way ANOVA with Dunnett's multiple comparison (N=5-7).

A



B



C




Figure 5. Mice with chronic visceral hypersensitivity (CVH) evoked by TNBS had increased spontaneous afferent firing and hypersensitivity in response to bladder distension. This effect was partially reversed by application of granisetron. (A). Afferent firing from bladders taken from sham mice, mice with acute visceral hypersensitivity (AVH) and mice with chronic visceral hypersensitivity (CVH), showing that firing rate was higher with chronic visceral hypersensitivity and partially rescued by application of the 5HT₃ receptor

antagonists granisetron. (B). The afferent response to bladder filling in bladders taken from sham mice, mice with acute visceral hypersensitivity (AVH) and mice with chronic visceral hypersensitivity (CVH) showing that firing rate was higher with chronic visceral hypersensitivity and partially rescued by application of the 5HT₃ receptor antagonists granisetron. * $P < 0.05$, and One-way ANOVA with Dunnett' s multiple comparison and Two- way ANOVA respectively (healthy control and CVH, N=6; acute TNBS, N=5; CVH, N=6; CVH+granisetron, N=6). (C). The afferent response to bladder filling in bladders taken from normal control mice before and after application of granisetron. These data show that in bladders taken from healthy control animals granisteron has no effect on the afferent response to bladder distension (N=5)








Figure 6 SERT mRNA expression in the urothelium was significantly attenuated in mice with CVH. (A) SERT mRNA expression was significantly reduced in urothelial cell cultures from CVH animals compared to control animals (* $P < 0.05$, unpaired Student's t-test healthy control; $N=4$, CVH; $N=6$). (B) TPH1 and (C) TPH2 mRNA expression was not significantly altered. (NS, unpaired Student's t-test healthy control; $N=4$, CVH; $N=6$).

A



B



C

	Traced Bladder Neurons	Non-traced Neurons
5-HT	60/69 (87.0%)	37/457 (8.1%)
2-Me-5HT	36/51 (70.6%)	32/349 (9.2%)

D




Figure 7. 5-HT and 2-Me-5HT induce calcium transients in bladder-innervating DRG neurons. (A) A high percentage of bladder projecting DRG neurons in both sham (91%) and mice with CVH (95%) express 5-HT₃ receptors (sham, N=3, n=77; CVH, N=3, n=74; N refers to number of animals, n indicates number of DRG neurons). (B) Calcium responses elicited by 5-HT (100 μ M) and 2-Me-5HT (100 μ M) from isolated bladder-innervating (traced), and non-traced LS DRG neurons. Each line represents an individual neuron. Bladder traced neurons are represented in blue, non-traced neurons are represented in black, and responding non-traced neurons are represented in orange. (C) Table

showing number of bladder-innervating and non-traced LS DRG neurons responding to 5-HT (100 μ M) (N=4 mice) and 2-Me-5HT (100 μ M) (N=4 mice). The percentage of bladder-innervating neurons responding to either to 5-HT and 2-Me-5HT is greater than responding neurons from the general DRG population. (D) Maximum change in fluorescent ratio (F340/380) of individual neurons in response to 5-HT and 2-Me-5HT in bladder-innervating (blue dots) and nontraced (orange dots) LS DRG. The magnitude of the calcium response elicited by 5-HT (100 μ M) is equivalent to that elicited by 2-Me-5HT (100 μ M) for both bladder-innervating DRGs ($p \geq 0.05$, One-way ANOVA, Tukey post-hoc test) and in the non-traced DRGs ($p \geq 0.05$, One-way ANOVA, Tukey post-hoc test).

Author contributions

All experiments were performed in Professor Grundy's laboratory at the University of Sheffield, United Kingdom except for TNBS-induced experiments which were conducted in the Visceral Pain Reserach Group Laboratory at the South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia. The following contributions were:

- Conducting experiments: NK, TO, SGC
- Design of experiments, analysis, interpretation of data, - DD, DG, NK and LG
- Production and editing of manuscript- DD, DG, NK, SMB and LG
- Funding and research support- DG and SB

Funding

This research was supported by a full PhD scholarship provided to N.K. from the Development and Promotion of Sciences and Technology Talents Project (DPST), Thailand. An ICS research fellowship was awarded to N.K. to conduct experiments at the SAHMRI, Adelaide, Australia. S.M.B is a National Health and Medical Research Council of Australia (NHMRC) R.D Wright Biomedical Research Fellow (APP1126378). Work in Adelaide was funded in part by NHMRC Australia Project Grant #1140297 to S.M.B.

Bibliography

Aaron, L.A., and D. Buchwald. 2001. A review of the evidence for overlap among unexplained clinical conditions. *Ann Intern Med.* 134:868-881.

- Ahn, J., T.M. Saltos, V.J. Tom, and S. Hou. 2018. Transsynaptic tracing to dissect supraspinal serotonergic input regulating the bladder reflex in rats. *Neurol Urodyn.* 37:2487-2494.
- Antoniou, E., G.A. Margonis, A. Angelou, A. Pikouli, P. Argiri, I. Karavokyros, A. Papalois, and E. Pikoulis. 2016. The TNBS-induced colitis animal model: An overview. *Ann Med Surg (Lond).* 11:9-15.
- Bellono, N.W., J.R. Bayrer, D.B. Leitch, J. Castro, C. Zhang, T.A. O'Donnell, S.M. Brierley, H.A. Ingraham, and D. Julius. 2017. Enterochromaffin Cells Are Gut Chemosensors that Couple to Sensory Neural Pathways. *Cell.* 170:185-198 e116.
- Berger, M., J.A. Gray, and B.L. Roth. 2009. The expanded biology of serotonin. *Annu Rev Med.* 60:355-366.
- Brierley, S.M., and D.R. Linden. 2014. Neuroplasticity and dysfunction after gastrointestinal inflammation. *Nat Rev Gastroenterol Hepatol.* 11:611-627.
- Brumovsky, P.R., and G.F. Gebhart. 2010. Visceral organ cross-sensitization - an integrated perspective. *Auton Neurosci.* 153:106-115.
- Castro, J., A.M. Harrington, S. Garcia-Caraballo, J. Maddern, L. Grundy, J. Zhang, G. Page, P.E. Miller, D.J. Craik, D.J. Adams, and S.M. Brierley. 2017. alphaConotoxin Vc1.1 inhibits human dorsal root ganglion neuroexcitability and mouse colonic nociception via GABAB receptors. *Gut.* 66:1083-1094.
- Chetty, N., I.M. Coupar, R. Chess-Williams, and K.P. Kerr. 2007. Demonstration of 5HT(3) receptor function and expression in the mouse bladder. *Naunyn Schmiedebergs Arch Pharmacol.* 375:359-368.
- Christianson, J.A., R. Liang, E.E. Ustinova, B.M. Davis, M.O. Fraser, and M.A. Pezzone. 2007. Convergence of bladder and colon sensory innervation occurs at the primary afferent level. *Pain.* 128:235-243.
- Coates, M.D., C.R. Mahoney, D.R. Linden, J.E. Sampson, J. Chen, H. Blaszyk, M.D. Crowell, K.A. Sharkey, M.D. Gershon, G.M. Mawe, and P.L. Moses. 2004. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. *Gastroenterology.* 126:1657-1664.
- Coelho, A., R. Oliveira, H. Cavaleiro, C.D. Cruz, and F. Cruz. 2018. Evidence for an urethro-vesical crosstalk mediated by serotonin. *Neurol Urodyn.* 37:2389-2397.
- Daly, D., and C. Chapple. 2013. Relationship between overactive bladder (OAB) and irritable bowel syndrome (IBS): concurrent disorders with a common pathophysiology? *BJU Int.* 111:530-531.
- Daly, D., W. Rong, R. Chess-Williams, C. Chapple, and D. Grundy. 2007. Bladder afferent sensitivity in wild-type and TRPV1 knockout mice. *J Physiol.* 583:663-674.
- Daly, D.M., L. Nocchi, M. Liaskos, N.G. McKay, C. Chapple, and D. Grundy. 2014. Age-related changes in afferent pathways and urothelial function in the male mouse bladder. *J Physiol.* 592:537-549.
- de Araujo, A.D., M. Mobli, J. Castro, A.M. Harrington, I. Vetter, Z. Dekan, M. Muttenthaler, J. Wan, R.J. Lewis, G.F. King, S.M. Brierley, and P.F. Alewood. 2014. Selenoether oxytocin analogues have analgesic properties in a mouse model of chronic abdominal pain. *Nat Commun.* 5:3165.
- Dwyer, D.F., N.A. Barrett, K.F. Austen, and C. Immunological Genome Project. 2016. Expression profiling of constitutive mast cells reveals a unique identity within the immune system. *Nat Immunol.* 17:878-887.

- Fitzgerald, J.J., E. Ustinova, K.B. Koronowski, W.C. de Groat, and M.A. Pezzone. 2013. Evidence for the role of mast cells in colon-bladder cross organ sensitization. *Auton Neurosci.* 173:6-13.
- Gabella, G., and C. Davis. 1998. Distribution of afferent axons in the bladder of rats. *J Neurocytol.* 27:141-155.
- Gershon, M.D., and J. Tack. 2007. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. *Gastroenterology.* 132:397-414.
- Glennon, R.A., M. Lee, J.B. Rangisetty, M. Dukat, B.L. Roth, J.E. Savage, A. McBride, L. Rauser, S. Hufeisen, and D.K. Lee. 2000. 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. *J Med Chem.* 43:1011-1018.
- Grundy, D. 2008. 5-HT system in the gut: roles in the regulation of visceral sensitivity and motor functions. *Eur Rev Med Pharmacol Sci.* 12 Suppl 1:63-67.
- Grundy, L., and S.M. Brierley. 2018. Cross-organ sensitization between the colon and bladder: to pee or not to pee? *Am J Physiol Gastrointest Liver Physiol.* 314:G301-G308.
- Grundy, L., R. Chess-Williams, S.M. Brierley, K. Mills, K.H. Moore, K. Mansfield, R. Rose'Meyer, D. Sellers, and D. Grundy. 2018a. NKA enhances bladder-afferent mechanosensitivity via urothelial and detrusor activation. *Am J Physiol Renal Physiol.* 315:F1174-F1185.
- Grundy, L., A. Erickson, and S.M. Brierley. 2019. Visceral Pain. *Annu Rev Physiol.* 81:261-284.
- Grundy, L., A.M. Harrington, J. Castro, S. Garcia-Caraballo, A. Deiteren, J. Maddern, G.Y. Rychkov, P. Ge, S. Peters, R. Feil, P. Miller, A. Ghatti, G. Hannig, C.B. Kurtz, I. Silos-Santiago, and S.M. Brierley. 2018b. Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction. *JCI Insight.* 3.
- Hall, J.D., C. DeWitte, T.J. Ness, and M.T. Robbins. 2015. Serotonin enhances urinary bladder nociceptive processing via a 5-HT₃ receptor mechanism. *Neurosci Lett.* 604:97-102.
- Hattori, T., P. Lluet, C. Rouget, M. Rekik, and M. Yoshiyama. 2017. Ketanserin and Naftopidil Enhance the Potentiating Effect of Alpha-Methyl-Serotonin on the Neurally-Induced Contraction of Human Isolated Urinary Bladder Muscle Strips. *Int Neurourol J.* 21:20-28.
- Hughes, P.A., S.M. Brierley, and L.A. Blackshaw. 2009. Post-inflammatory modification of colonic afferent mechanosensitivity. *Clin Exp Pharmacol Physiol.* 36:1034-1040.
- Keating, C., M. Beyak, S. Foley, G. Singh, C. Marsden, R. Spiller, and D. Grundy. 2008. Afferent hypersensitivity in a mouse model of post-inflammatory gut dysfunction: role of altered serotonin metabolism. *J Physiol.* 586:4517-4530.
- Kodama, M., and Y. Takimoto. 2000. Influence of 5-hydroxytryptamine and the effect of a new serotonin receptor antagonist (sarpogrelate) on detrusor smooth muscle of streptozotocin-induced diabetes mellitus in the rat. *Int J Urol.* 7:231-235.
- Kullmann, F.A., H.H. Chang, C. Gauthier, B.M. McDonnell, J.C. Yeh, D.R. Clayton, A.J. Kanai, W.C. de Groat, G.L. Apodaca, and L.A. Birder. 2018. Serotonergic paraneurons in the female mouse urethral epithelium and their potential role in peripheral sensory information processing. *Acta Physiol (Oxf).* 222.

- Linden, D.R., J.X. Chen, M.D. Gershon, K.A. Sharkey, and G.M. Mawe. 2003. Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. *Am J Physiol Gastrointest Liver Physiol.* 285:G207-216.
- Linden, D.R., K.F. Foley, C. McQuoid, J. Simpson, K.A. Sharkey, and G.M. Mawe. 2005. Serotonin transporter function and expression are reduced in mice with TNBS-induced colitis. *Neurogastroenterol Motil.* 17:565-574.
- Malykhina, A.P. 2007. Neural mechanisms of pelvic organ cross-sensitization. *Neuroscience.* 149:660-672.
- Malykhina, A.P., C. Qin, B. Greenwood-van Meerveld, R.D. Foreman, F. Lupu, and H.I. Akbarali. 2006. Hyperexcitability of convergent colon and bladder dorsal root ganglion neurons after colonic inflammation: mechanism for pelvic organ cross-talk. *Neurogastroenterol Motil.* 18:936-948.
- Matsumoto-Miyai, K., E. Yamada, E. Shinzawa, Y. Koyama, S. Shimada, M. Yoshizumi, and M. Kawatani. 2016. Serotonergic regulation of distention-induced ATP release from the urothelium. *Am J Physiol Renal Physiol.* 310:F646-F655.
- McCorvy, J.D., and B.L. Roth. 2015. Structure and function of serotonin G protein-coupled receptors. *Pharmacol Ther.* 150:129-142.
- Mitra, S., S. Malhotra, K.S. Naruganahalli, and A. Chugh. 2007. Role of peripheral 5HT_{1A} receptors in detrusor over activity associated with partial bladder outlet obstruction in female rats. *Eur J Pharmacol.* 561:189-193.
- Motavallian-Naeini, A., M. Minaian, M. Rabbani, and P. Mahzuni. 2012. Anti-inflammatory effect of ondansetron through 5-HT₃ receptors on TNBS-induced colitis in rat. *EXCLI J.* 11:30-44.
- Motavallian, A., M. Minaian, M. Rabbani, S. Andalib, and P. Mahzouni. 2013. Involvement of 5HT₃ Receptors in Anti-Inflammatory Effects of Tropisetron on Experimental TNBS-Induced Colitis in Rat. *Bioimpacts.* 3:169-176.
- Nicholson, R., J. Small, A.K. Dixon, D. Spanswick, and K. Lee. 2003. Serotonin receptor mRNA expression in rat dorsal root ganglion neurons. *Neurosci Lett.* 337:119-122.
- Osteen, J.D., V. Herzog, J. Gilchrist, J.J. Emrick, C. Zhang, X. Wang, J. Castro, S. Garcia-Caraballo, L. Grundy, G.Y. Rychkov, A.D. Weyer, Z. Dekan, E.A. Undheim, P. Alewood, C.L. Stucky, S.M. Brierley, A.I. Basbaum, F. Bosmans, G.F. King, and D. Julius. 2016. Selective spider toxins reveal a role for the Nav1.1 channel in mechanical pain. *Nature.* 534:494-499.
- Qin, C., A.P. Malykhina, H.I. Akbarali, and R.D. Foreman. 2005. Cross-organ sensitization of lumbosacral spinal neurons receiving urinary bladder input in rats with inflamed colon. *Gastroenterology.* 129:1967-1978.
- Rekik, M., P. Lluel, and S. Palea. 2011. 5-Hydroxytryptamine potentiates neurogenic contractions of rat isolated urinary bladder through both 5-HT(7) and 5-HT(2C) receptors. *Eur J Pharmacol.* 650:403-410.
- Spencer, N.J., S. Greenheigh, M. Kyloh, T.J. Hibberd, H. Sharma, L. Grundy, S.M. Brierley, A.M. Harrington, E.A. Beckett, S.J. Brookes, and V.P. Zagorodnyuk. 2018. Identifying unique subtypes of spinal afferent nerve endings within the urinary bladder of mice. *J Comp Neurol.* 526:707-720.
- Su, X., and G.F. Gebhart. 1998. Mechanosensitive pelvic nerve afferent fibers innervating the colon of the rat are polymodal in character. *J Neurophysiol.* 80:2632-2644.

- Weitzman, G., S.J. Galli, A.M. Dvorak, and I. Hammel. 1985. Cloned mouse mast cells and normal mouse peritoneal mast cells. Determination of serotonin content and ability to synthesize serotonin in vitro. *Int Arch Allergy Appl Immunol.* 77:189-191.
- Yoshida, A., S.Y. Y, M. Kaibara, K. Taniyama, and N. Tanaka. 2002. 5-Hydroxytryptamine receptors, especially the 5-HT₄ receptor, in guinea pig urinary bladder. *Jpn J Pharmacol.* 89:349-355.
- Zagorodnyuk, V.P., M. Costa, and S.J. Brookes. 2006. Major classes of sensory neurons to the urinary bladder. *Auton Neurosci.* 126-127:390-397.
- Zagorodnyuk, V.P., I.L. Gibbins, M. Costa, S.J. Brookes, and S.J. Gregory. 2007. Properties of the major classes of mechanoreceptors in the guinea pig bladder. *J Physiol.* 585:147-163.

Competing interests

We can confirm that none of the authors has any conflicts of interest.